On September 28, Frost & Sullivan (Frost &The 2022 First New Investment Expo and the 16th Frost & Sullivan Global Growth, Innovation & Leadership Summit Biotech Investment Forum, co-hosted by Frost & Sullivan and LeadLeo in collaboration with Titanium Media and Roadshow China, and co-organized by LeadLeo, successfully concluded.
September 28, 2022
Today, the biotechnology sector has become a dazzling pearl in the capital market. The opening of the Hong Kong Stock Exchange and the Sci-Tech Innovation Board to unprofitable enterprises has further catalyzed a capital boom. However, due to unfavorable macroeconomic factors in recent years and structural challenges faced by biotechnology companies themselves, the performance of biotechnology companies in the capital market varies. Therefore, how to discover new tracks and seize new opportunities in an environment of coexisting crises has become a hot topic among investors and entrepreneurs.
The theme of this forum isWith the theme of 'New Trends in Biotech Investment and Financing', eight heavyweight guests and three Frost & Sullivan healthcare industry experts were invited. A gathering of biotech companies, investment institutions, and professional service providers was convened to focus on new trends in biotech investment and financing, explore forward-looking investment opportunities in biotechnology, and discuss the successful paths for biotech companies in the capital market. At the same time, Frost & Sullivan's GlobalWinning Enterprises of the 2022 GIL Awards for Growth, Innovation and Leadership in the Biotechnology Field
Dr. Wang Xin, Global Partner at Frost & Sullivan and President of Greater China, Founder and Chairman of LeadLeo, delivered a welcome speech for the conference, which was grandly opened. Dr. Wang Xin stated that over the past decade or so, the development of biotech companies in China has essentially been about 'crossing the river by feeling the stones'. The rapid market explosion was initiated byIn 2018, the Hong Kong Stock Exchange issued Chapter 18A. Capital investment is an indispensable and important factor in driving the growth of biotech companies, and it is crucial for promoting research and development and accelerating business success in the life sciences industry. He pointed out that in the face of the inevitable cyclical nature of the industry, to find more certain investment opportunities in the biopharmaceutical field, it is necessary to conduct long-term and continuous in-depth research on technological trends, policy changes, and industry dynamics in the biotechnology sector. Frost & Sullivan's Healthcare Practice has offices in ChinaThe analyst team of over 60 people has been dedicated to in-depth industry and corporate research for a long time. They can seamlessly connect with each other while helping to meet the supply and demand sides of investment and financing.
Dr. Wang Xin, Global Partner at Frost & Sullivan and President of Greater China, Founder and Chairman of LeadLeo, delivered a speech at the conference.
Discovering Hidden Dragons in High-Potential Tracks: Announcement of the 2022 Biotechnology Growth, Innovation and Leadership Awards
At the meeting, Mr. Wang Chenhui, Managing Partner and Executive Vice President of Frost & Sullivan Greater China Region, and Co-founder and President of LeadLeo, presented their respective wins for this yearBeijing Zehui Chenxing Biotechnology Co., Ltd., winner of the GIL Award, was presented with the 'Global Multi-Potent Stem Cell Drug Leadership Award', and Chongqing Jinshan Medical Robotics Co., Ltd. was awarded the 'China Medical Robotics Innovation Award'.
Beijing Zehui Chenxing Biotechnology Co., Ltd.Dr. Jia Yi, CMO, takes the stage to receive the award
Ms. Wang Liao, founder of Chongqing Jinshan Medical Robotics Co., Ltd., took the stage to receive her award
Focus on Biotechnology Hotspots:The white paper "Current Situation and Future Development Trends of the CDMO Industry" has been officially released.
Mr. Li Dongyi, Director of Healthcare Consulting at Frost & Sullivan, delivered a grand launch ofThe 'Report on the Current Situation and Future Development Trends of the CDMO Industry' aims to conduct an in-depth analysis of China's CDMO industry. It explores the industry value of CDMO from various aspects such as industry overview, capital enthusiasm, and competitive landscape. It investigates the driving force factors behind industry development trends and tracks the iterative context of production technology.
This report focuses onWhile analyzing the overall operational status of the CDMO industry, this report focuses on the current development status of various CDMO sub-sectors. It conducts market size analysis of the overall pattern of the CDMO industry in China and globally, as well as key tracks within it. It reflects the development history of various sub-sectors in China's CDMO industry over the past and makes prospects predictions for the growth potential of the CDMO market in the future.
We would like to express our special gratitude to Kanglong Chemical Technology, Dongyao Pharmaceutical, and Yaohai Biotechnology for their support of this report.
Kang Long Huacheng Securities' General Supervising Officer Yang (left), Dongyao Pharmaceutical's Financial Director Xiao Ben (middle), and Wang Manchao, Founder Partner, Director and General Manager of Yaohai Biotechnology (right).
Three major professional topics, discussing the development and future of the biotechnology investment and financing market
The first session of the conference was delivered by Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, who shared the theme of 'Review and Outlook of the Biopharmaceutical Investment and Financing Market in 2022
Mr. Mao Hua said that the biopharmaceutical capital market has not entered a winter period, and the investment and financing market tends towards"Caution + rationality," investors tend to invest earlier, targeting smaller enterprises with more hardcore technology. This provides a certain degree of maneuverability for investment institutions, even in the early stages, where high valuations are still given to technology-intensive companies.
In addition, Mr. Mao Hua also stated that industrial capital has emerged as a new force, and the professional investment institutions and financing relay mechanism are gradually improving, promoting the healthy development of the biotechnology industry. Finally Mr. Mao Hua summarized that investment and financing complement each other with enterprise operations, and in the past, products reached clinical trialsIn Phase II, enterprises need to plan pricing, sales strategies after product launch, and at what discount rates they can enter the medical insurance market. Now, enterprises need to go a step further by making early plans during financing.
Partner and Managing Director of Frost & Sullivan Greater China Region Mr. Mao Hua
Dr. Wang Shu, Deputy General Manager of Yikelei Biotechnology, shared the theme 'Because We Believe So see"An Overview of Synthetic Biology," Dr. Wang Shu systematically reviewed the definition, research content, and industry overview of synthetic biology. He pointed out that synthetic biology has ushered in a new era of scientific research, and its application potential is gradually emerging. The core technology of synthetic biology manufacturing is the construction of efficient microbial cell factories. All pathways need to be assembled, balanced, and optimized within this factory to achieve results, thereby converting biomass raw materials into various end products. How to expand the variety of chemicals produced by microbial cells and how to improve cell production efficiency are currently two very critical issues limiting the industrialization of cell factories. Dr. Wang Shu stated that synthetic biology is a field that many countries have attached great importance to in recent years. Especially driven by carbon neutrality, the competitiveness of synthetic biology has gradually become prominent, and its future development potential cannot be underestimated.
Vice General Manager of Yikelei Biotechnology Dr. Wang Shu
Mr. Zhu Jielun, Chief Financial Officer and Chief Investment Officer of Feipeng Group, delivered a keynote speech titled "How Biotech Companies Efficiently Meet Their Financing Needs." He believes that the essence of the capital market is an amplifier, and participants generally have a herd mentality, following trends and magnifying them. At the same time, he believes that in the vast ocean of the capital market, discovering, grasping, and utilizing cycles is the key to success. Finally, Mr. Zhu Jielun summarized the high-qualityThe qualities that IR needs to possess include external anticipation management, internal information integration, and sincerity. It is also necessary to convey real-time market capitalization information within the business's departments.
Chief Financial Officer and Chief Investment Officer of Feipeng Group Mr. Zhu Jielun
Roundtable Discussion: Exploring the New Pattern of Industry Development
A roundtable forum was specially set up at this summit, where leaders and experts from multiple companies shared their industry experiences and insights on hot topics such as how biotech companies choose diverse listing locations.
Mr. Ren Mengqi, Executive General Manager of Investment Banking at CICC; Mr. Geng Ke, Managing Partner of Meimes Law Firm; Mr. Fei Fan, Co-Head of Life Sciences and Healthcare at EY Greater China; Mr. Li Ankang, Chief Financial Officer and Chief Strategy Officer of Tengsheng Bopharm; and Mr. Wang Shuguang, Managing Partner and General Manager of Shanghai Wenzhou Investment Management Co., Ltd., will discussA in-depth discussion on 'hot topics such as how biotech companies choose diverse listing locations' was held, with Mr. Zhu Yi, Executive Director of Frost & Sullivan, serving as the moderator for this roundtable.
Mr. Ren Mengqi, Executive General Manager of Investment Banking at CICC, stated that although the capital market has recently entered a low point, it has also given investors time to calm down and identify what truly constitutes a good company.
Mr. Geng Ke, Managing Partner of Meimas Law Firm, mentioned recent bills and cases affecting the capital market of the biotech industry, pointing out that the review of Chinese companies acquiring US companies has become increasingly stringent.
Mr. Fai Fan, Co-Head of Life Sciences and Healthcare at EY Greater China, said that in the context of an overall pessimistic environment, businesses need to"Wait, save, and finance," the first step is to wait until the overall environment improves. Second is to save, hold onto cash wisely, and make full use of it. Finally, is finance. Although companies now face issues such as declining valuations when financing, they still need money to operate.
Mr. Li Ankang, Chief Financial Officer and Chief Strategy Officer of Tengsheng Boyao, stated that there are many uncertainties in the current market, and businesses need to adjust their business priorities. In addition, it is necessary to raise the standards for doing business and products, as enterprises are facing a more competitive market and more discerning investors in the current environment.
Mr. Wang Shuguang, the managing partner and general manager of Shanghai Wen Zhou Investment Management Co., Ltd., stated that his institution is engaged in earlier-stage investments and has not experienced difficulties in financing or the arrival of a severe winter market. As an investment institution, it is necessary to prioritize investment research, understand national policy trends, and identify companies whose products truly have clinical advantages.
In addition, as one of the representatives of the partners, Mr. Zhou Yujian, managing partner of PowerSquare Health Fund, sent his blessings to the conference via video. Mr. Zhou Yujian stated that PowerSquare Health Fund is honored to join hands with Frost & Sullivan to play a role in the global development layout of Chinese biopharmaceutical enterprises and contribute together.
PowerHealth Fund Management Partnership Mr. Zhou Yujian
The conference successfully concluded amidst warm applause. We would like to express our gratitude to all the distinguished guests and experts for their support of the Frost & Sullivan Biopharmaceutical Technology Investment Forum.
